Furthermore, the different effects of GPCR antagonists during versus after CH might be explained by changes in cross-talk inhibition between GQ and GS pathways, activated by 5HT2 and A2A receptors respectively. The gene discussed is HTR2A; the disease is cyclic hematopoiesis.